Efficacy of Adjunctive Low-Level Light Therapy to Intense Pulsed Light for Meibomian Gland Dysfunction
Launched by CHULALONGKORN UNIVERSITY · Jun 16, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether adding low-level light therapy (LLLT) to intense pulsed light (IPL) treatments can improve care for people suffering from meibomian gland dysfunction (MGD). MGD is a condition that can cause dry eyes and discomfort due to problems with the glands that produce oils in the eyelids. The study will compare two groups: one receiving just IPL treatment and the other receiving both IPL and LLLT, to see if the combination works better.
To participate in this trial, you should be between 65 and 74 years old and have a moderate to severe level of MGD. However, certain individuals will not be eligible, such as those who have had eye surgery recently, wear contact lenses, or have other specific medical conditions. Participants will receive either the combined treatment or IPL alone and will be monitored for improvements in their eye health. If you meet the criteria and are interested, this trial could help find better treatment options for MGD.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • MGD severity level 2 and above according to the international workshop on MGD
- • Fitzpatrick skin type of 1-4 according to sun sensitivity characteristics and appearance of the skin color
- Exclusion Criteria:
- • History of previous ocular trauma or surgery within the past six months
- • Contact lens-wearing patients
- • Patients with skin-pigmented lesions in the treatment area
- • Pregnancy or breastfeeding patients
- • Patients with any uncontrolled ocular or systemic diseases
About Chulalongkorn University
Chulalongkorn University, one of Thailand's premier academic institutions, is dedicated to advancing medical research and enhancing healthcare outcomes through innovative clinical trials. With a strong emphasis on collaboration and interdisciplinary approaches, the university leverages its extensive resources and expertise in various medical fields to conduct rigorous scientific investigations. Chulalongkorn University aims to contribute to global health advancements by fostering a culture of excellence in research, education, and community service, ultimately improving patient care and public health standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkok, , Thailand
Patients applied
Trial Officials
Chatchada Kharuhayothin
Principal Investigator
Ophthalmology department, Faculty of medicine, Chulalongkorn university
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported